A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
for Alzheimer Disease
Drug: KarXT
39 locations incl. Chandler
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 55 - 90
Code: NCT07011745·Phase 3·Recruiting